US EditionJoint Comment on FDA's Draft Guidance for Sepsis Prevention in HCT/Ps
Summary by America's Blood Centers
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Joint Comment on FDA's Draft Guidance for Sepsis Prevention in HCT/Ps
America’s Blood Centers (ABC), the Association for the Advancement of Blood and Biotherapies (AABB), and the American Red Cross (ARC) have submitted this joint response to the FDA’s draft guidance on reducing disease transmission risks associated with sepsis in human cells, tissues, and cellular/tissue-based products (HCT/Ps). While supporting the FDA’s mission to enhance HCT/P safety, these organizations raise critical concerns about the propos…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
